Developing chemically modified mRNA for new human therapies
Toward synthetic chemically defined mRNA for human therapeutics
['FUNDING_R21'] · WAKE FOREST UNIVERSITY HEALTH SCIENCES · NIH-10927440
This study is working on making mRNA treatments better so they can help people with genetic diseases, aiming for safer and longer-lasting therapies that go beyond just vaccines.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WAKE FOREST UNIVERSITY HEALTH SCIENCES (nih funded) |
| Locations | 1 site (WINSTON-SALEM, UNITED STATES) |
| Trial ID | NIH-10927440 on ClinicalTrials.gov |
What this research studies
This research focuses on improving messenger RNA (mRNA) technology to create more effective human therapeutics beyond vaccines. By chemically modifying mRNA, the researchers aim to enhance its stability and effectiveness, allowing it to be used for treating genetic diseases. The approach involves synthesizing mRNA in a way that overcomes current limitations related to manufacturing and patient safety. Patients may benefit from therapies that can provide longer-lasting effects and more precise treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with genetic disorders or those who may benefit from advanced mRNA-based therapies.
Not a fit: Patients with conditions that do not involve genetic components or those who are not eligible for mRNA therapies may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies for genetic diseases and other conditions, significantly improving patient outcomes.
How similar studies have performed: Other research has shown success with chemically modified nucleic acid drugs, indicating a promising avenue for mRNA therapeutics.
Where this research is happening
WINSTON-SALEM, UNITED STATES
- WAKE FOREST UNIVERSITY HEALTH SCIENCES — WINSTON-SALEM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GAGNON, KEITH THOMAS — WAKE FOREST UNIVERSITY HEALTH SCIENCES
- Study coordinator: GAGNON, KEITH THOMAS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.